Original Research
A retrospective review of conventional versus hypo-fractionated pelvic radiotherapy for locally advanced cervical cancer, in limited-resource countries: The Uganda experience
Submitted: 28 May 2021 | Published: 22 September 2021
About the author(s)
Awusi Kavuma, Department of Radiotherapy, Uganda Cancer Institute, Kampala, UgandaIsrael Luutu, Department of Radiotherapy, Uganda Cancer Institute, Kampala, Uganda
Solomon Kibudde, Department of Radiotherapy, Uganda Cancer Institute, Kampala, Uganda
Cissy Bangidde, Department of Radiotherapy, Uganda Cancer Institute, Kampala, Uganda
Abstract
Background: Cervical cancer incidence in Uganda is 54.8 per 100 000 population. We annually treat over 800 new cervical cancers (40% of the workload), which is challenging to treat such numbers in limited resources settings. From July 2011, we commenced the use of hypo-fractionated radiotherapy (HFRT) of 45 Gy/15 fraction (#) as an alternative to conventional fractionated radiotherapy (CFRT) of 50 Gy/25#, for treatment of locally advanced cervical cancer (LACC).
Aim: To compare the 5-year follow-up treatment outcomes between CFRT and HFRT.
Settings: The study analysed patients treated at the Uganda Cancer Institute – a limited resource institution.
Methods: This was a non-randomised, retrospective study, where 414 patients’ files were reviewed according to demographic, clinical, radiotherapy fractionations and outcomes. Inclusion criteria were International Federation of Gynecology and Obstetrics stages IIB–IIIB cervical cancer cases and had completed external beam radiotherapy and intracavitary radiotherapy.
Results: Squamous cell carcinomas were 93.6% and adenocarcinomas were 3.0%. The median age was 49.5 (interquartile range [IQR]: 40.0–56.0) years. Stages IIB/IIIA/IIIB were 36.2%, 8.2%, 55.6%, respectively. Human immunodeficiency virus serology was positive, negative, and unknown in 70 (16.9%), 116 (28.0%) and 228 (55.1%), respectively. Concurrent chemo-radiation was administered in 182 (44.0%) patients. Conventional fractionated radiotherapy and HFRT were 221 (53.4%) and 193 (46.6%), respectively. At 6 months, the overall response rate was 73.3% for CFRT compared with 67.6% for HFRT (p = 0.085), whilst the grades 0–1 toxicities were 94.5% and for 94.7% CFRT and HFRT, respectively (p = 0.080). At 60 months, the survival probabilities were 44.9% for CFRT and 46.6% for HFRT (p = 0.293).
Conclusion: There is no significant statistical difference between CFRT and HFRT for the treatment of LACC. The HFRT could be considered for high volume limited resource settings.
Keywords
Metrics
Total abstract views: 3201Total article views: 6151
Crossref Citations
1. Virtual radiotherapy plan quality education: Perspectives from a global setting
Caroline M. Colbert, Emily Kruse, Dustin Jacqmin, Jose Carlos Pichardo, Chunhao Wang, Leah K. Schubert, Stephanie Bennett, Mu-Han Lin, Lindsey Olsen, Benjamin Li, Minsun Kim
Physica Medica vol: 137 first page: 105069 year: 2025
doi: 10.1016/j.ejmp.2025.105069
2. A comparative analysis of hypofractionated versus conventional radiotherapy for cervical cancer in a resource-limited setting: a prospective study
Abba Mallum, Maureen Bilinga Tendwa, Rakiya Saidu, William Swanson, Paul Phan, Heng Li, Twalib Ngoma, Stephen Avery, M. Saiful Huq, John M. Akudugu, Wilfred Ngwa, Luca Incrocci, Mariza Vorster
Frontiers in Oncology vol: 15 year: 2025
doi: 10.3389/fonc.2025.1552346
3. Cervical cancer survival times in Africa
Emmanuel Kwateng Drokow, Fangnon Firmin Fangninou, Clement Yaw Effah, Clement Agboyibor, Yunfeng Zhang, Francisca Arboh, Marie-Anne Deku, Wu Xinyin, Yue Wang, Kai Sun
Frontiers in Public Health vol: 10 year: 2022
doi: 10.3389/fpubh.2022.981383
4. Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer
Won Kyung Cho, Won Park, Sang-Won Kim, Kang Kyu Lee, Ki Jung Ahn, Jin Hwa Choi
JAMA Oncology vol: 10 issue: 6 first page: 737 year: 2024
doi: 10.1001/jamaoncol.2024.0565
5. Moderated Hypofractionated Online Adaptive Radiotherapy in Locally Advanced Cervical Cancer: A Case Report
Zheng Zeng, Fuquan Zhang, Junfang Yan
Cureus year: 2024
doi: 10.7759/cureus.66552



